Article Sidebar

PDF
Date Published: 15/04/2022
Abstract Views: 125
Views PDF: 94
DOI: https://doi.org/10.51298/vmj.v511i1.2056
Issue
Vol. 511 No. 1 (2022)
Section
Các bài báo
How to Cite
Tấn, Đỗ ., Thị Thu Thuỷ, P. ., & Thị Hồng Nhung, N. . (2022). IMPACTING FACTORS FOR OUTCOME OF FIXED-COMBINATION BRINMONIDIN AND BRINZOLAMID (SIMBRINZA) IN GLAUCOMA TREATMENT. Vietnam Medical Journal, 511(1). https://doi.org/10.51298/vmj.v511i1.2056

IMPACTING FACTORS FOR OUTCOME OF FIXED-COMBINATION BRINMONIDIN AND BRINZOLAMID (SIMBRINZA) IN GLAUCOMA TREATMENT

Đỗ Tấn1,, Phạm Thị Thu Thuỷ2, Nguyễn Thị Hồng Nhung1
1 Central Eye Hospital
2 Hanoi Medical University

Main Article Content

Abstract

Objectives: To evaluation some impacting factor for IOP lowering effect of fixed-combination Simbrinza in glaucoma treatment. Subjects and methodology: The prospective descriptive study. A total of 50 eyes of 30 glaucoma patients over 18 years old where target IOP has not been reached by one antiglaucoma medication. The patients were given a drop of Simbrinza and IOP was taken after 2 hours. If IOP reduction of at least 25% without side effect was achieved, then treatment was continued twice a day. The patients were followed up at 1 week, 1 month and 3 months. Results: There were some relating factors for IOP reduction capability of fixed-combination Simbrinza such as duration of disease, IOP, number of IOP lowering medications before treatment. Rate of IOP reduction of ≥ 40% was higher in duration of disease < 1 month group than duration of disease > 6-month group. Higher pre-treatment IOP group had higher rate of IOP reduction of ≥ 40%. There were no significant relation betwween age, gender, type glaucoma, disease stage, history and treatment outcome. Conclusion: The significant impacting factors for reduing intraocular pressure of fixed-combination Simbrinza in treatment glaucoma were duration of disease, pre treatment IOP, number of IOP lowering medications before treatment.

Article Details

Keywords

Simbrinza, glaucoma, IOP

References

1. Kumarasamy NA, Lam FS, Wang AL, Theoharides T. Glaucoma: Current and Developing Concepts for Inflammation, Pathogenesis and Treatment. European Journal of Inflammation. 2006;4.
2. Vijaya L, et al. Prevalence and causes of low vision and blindness in an urban population [The Chennai Glaucoma Study. Indian J Ophthalmol] 2014.
3. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112(5):863-8687.
4. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113(3):431-436.
5. Petrov SY, Zinina VS, Volzhanin AV. [The role of fixed dose combinations in the treatment of primary open-angle glaucoma]. Vestn Oftalmol. 2018;134(4):100-107.
6. Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T. Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension. Adv Ther. 2014;31(12):1213-1227.
7. Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014;121(12):2348-2355.
8. Feldman RM, Katz G, McMenemy M, Hubatsch DA, Realini T. A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004%. American Journal of Ophthalmology. 2016;165:188-197
9. Kóthy P, Holló G. Real-life experience of using brinzolamide/brimonidine fixed drop combination in a tertiary glaucoma centre. Int Ophthalmol. 2020;40(2):377-383.